A Trial Protocol of Biweekly TAS-102 and Bevacizumab as Third-Line Chemotherapy for Advanced/Recurrent Colorectal Cancer: A Phase II Multicenter Clinical Trial (The TAS-CC4 Study)

Background: Treatment with TAS-102 has significantly improved the progression-free survival (PFS) and overall survival (OS) of patients with metastatic colorectal cancer (mCRC). Reportedly, the combination of TAS-102 plus bevacizumab extends the median PFS. The present study aimed to confirm the eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshida, Yoichiro, Yamada, Takeshi, Matsuoka, Hiroshi, Sonoda, Hiromichi, Fukazawa, Atsuko, Yoshida, Hiroshi, Ishida, Hideyuki, Hirata, Keiji, Hasegawa, Suguru, Sakamoto, Kazuhiro, Otsuka, Toshiaki, Koda, Keiji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japan Society of Coloproctology 2019
Materias:
Trial Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6774740/
https://www.ncbi.nlm.nih.gov/pubmed/31583329
http://dx.doi.org/10.23922/jarc.2018-043

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6774740/
https://www.ncbi.nlm.nih.gov/pubmed/31583329
http://dx.doi.org/10.23922/jarc.2018-043

Ejemplares similares